AUTHOR=de Almeida Felipe Campos , Berzoti-Coelho Maria G. , Toro Diana Mota , Cacemiro Maira da Costa , Bassan Vitor Leonardo , Barretto Gabriel Dessotti , Garibaldi Pedro Manoel Marques , Palma Leonardo Carvalho , de Figueiredo-Pontes Lorena Lobo , Sorgi Carlos Arterio , Faciolli Lucia Helena , Gardinassi Luiz Gustavo , de Castro Fabíola Attié TITLE=Bioactive Lipids as Chronic Myeloid Leukemia’s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors JOURNAL=Frontiers in Immunology VOLUME=Volume 13 - 2022 YEAR=2022 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.840173 DOI=10.3389/fimmu.2022.840173 ISSN=1664-3224 ABSTRACT=
Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that expresses the Philadelphia chromosome and constitutively activated Bcr-Abl tyrosine kinase in hematopoietic progenitor cells. Bcr-Abl tyrosine-kinase inhibitors (TKI) do not definitively cure all CML patients. The efficacy of TKI is reduced in CML patients in the blastic phase—the most severe phase of the disease—and resistance to this drug has emerged. There is limited knowledge on the underlying mechanisms of disease progression and resistance to TKI beyond